Rhythm Pharmaceuticals Inc. officer Joseph J. Shulman filed a Form 144 notice on November 18, 2026, disclosing a proposed sale of 45,921 shares of common stock on the Nasdaq exchange, with an aggregate market value of $5,354,847.81.

Key Highlights

  • Proposed seller: Joseph J. Shulman, identified as an officer of Rhythm Pharmaceuticals Inc.
  • Shares to be sold: 45,921 shares of common stock, with an aggregate market value of $5,354,847.81.
  • Shares outstanding: 69,330,906 shares of common stock outstanding, according to the filing.
  • Acquisition sources: 40,467 shares acquired on November 18, 2026 via exercise of stock options from the issuer; 5,454 shares acquired on February 1, 2025 via restricted stock units from the issuer.
  • Approximate date of sale: November 18, 2026, through broker Morgan Stanley Smith Barney LLC Executive Financial Services.
  • 10b5-1 plan: The filing indicates a plan adoption or instruction date of December 15, 2025.
  • Prior sales: The filing reports nothing to report under securities sold during the past three months.

Shulman's Proposed Sale: Acquisition Background and Sale Details

According to the Form 144 filing, Joseph J. Shulman, an officer of Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM), filed notice of a proposed sale of 45,921 shares of the company's common stock. The filing lists the broker as Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, 8th Floor, New York, NY 10004, with an approximate sale date of November 18, 2026.

The filing discloses two separate acquisition transactions underlying the proposed sale. A total of 40,467 shares were acquired on November 18, 2026, through the exercise of stock options from the issuer, with payment made in cash on the same date. An additional 5,454 shares were acquired on February 1, 2025, via restricted stock units from the issuer. A remark in the filing states: "The securities to be sold were acquired upon the vesting of restricted stock units during the period of 02/01/2025 through 02/16/2025."

The filing notes that Shulman is relying on Rule 10b5-1, with a plan adoption or instruction date of December 15, 2025. The aggregate market value of the 45,921 shares proposed for sale is listed as $5,354,847.81, against a total of 69,330,906 shares of common stock outstanding. The filing reports no sales of Rhythm Pharmaceuticals securities by Shulman in the three months preceding this notice.

What Was Disclosed

Rhythm Pharmaceuticals officer Joseph J. Shulman filed a Form 144 on November 18, 2026, disclosing a proposed sale of 45,921 common shares with an aggregate market value of $5,354,847.81, acquired through stock option exercises and restricted stock unit vestings, under a 10b5-1 plan adopted December 15, 2025.